Brief: XBiotech Announces Granting Of Canadian Patent For Treatment Of Dermatological Pathologies
Brief: XBiotech Announces Medical Research Council Funding
Brief: Xbiotech Added To Russell 3000® Index
Brief: XBiotech Says Public Offering Of 4.85 Million Common Shares Priced At $8.25 Per Share
U.S. STOCKS ON THE MOVE-Steel stocks, refiners, automakers
U.S. STOCKS ON THE MOVE-Automakers, Banks, Constellation Brands,
XBiotech drops on $40 mln equity raise
U.S. STOCKS ON THE MOVE-Chipmakers, tech stocks, Gap
Brief: XBiotech Says Public Offering Of 4.85 Million Common Shares Priced At $8.25 Per Share
Brief: Xbiotech Announces Public Offering Of Common Shares
Brief: Xbiotech Announces Plan To Launch Randomized Phase 2B Study Of Bermekimab In Hidradenitis Suppurativa
Brief: Xbiotech May Sell Up To 4.3 Mln Shares
Brief: XBiotech Inc Says Gave Notice Of Termination Of Common Stock Sales Agreement
Brief: Phase 2 Clinical Trial Of Bermekimab Shows Potential New Standard Of Care For Treatment Of Hidradenitis Suppurativa
Brief: Results From Phase 2 Clinical Trial Of Bermekimab In The Treatment Of Atopic Dermatitis
Brief: Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction In Pain
U.S. STOCKS ON THE MOVE-Oil stocks, retail stocks, Capricor Therapeutics
U.S. STOCKS ON THE MOVE-Retail stocks, Capricor, GenMark Diagnostics
Brief: XBiotech's Results From Phase 2 Atopic Dermatitis Study Suggest New Drug To Treat Skin Disease